Course Information for Audit

This educational site can still be audited free of charge. As an added feature, it is now available for accreditation for pharmacists

Course Information for Accreditation

The following information pertains to accreditation only. Before you proceed to registration, please review the learning objectives and content of the entire site.

Target Audience
Geriatric health-care practitioners

Accreditation
At this time we are offering CE for pharmacists only. The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Site Development Date: June 2001 Site Reviewed: December 2004 CE Release Date: May 1, 2005 CE Expiration Date: May 1, 2008

This program (INDIVIDUAL PROGRAM NUMBER 203-999-05-022-H01) qualifies for 0.20 CEUs (2.0 contact hours) of continuing pharmacy education. CEUs will be awarded provided that the participant reviews this site and scores 70% or better on the post test that follows. To receive a statement of credit, please complete the examination and evaluation that follows this program. A statement will be awarded and mailed to you within 4-6 weeks.

Site Development Author:
Manju T. Beier, Pharm..D., FASCP
President, Geriatric Consultant Resources, LLC
Clinical Assistant Professor, College of Pharmacy
University of Michigan, Ann Arbor, Michigan, USA

Learning Objectives
Upon completion of this program, the participant should be able to:

1. Describe the prevalence and economic burden of osteoporosis and osteoporotic fractures in the United States.

2. Discuss the bone remodeling process and describe the changes in this process that result in osteoporosis.

3. Enumerate the WHO criteria for the definition of osteoporosis in adult women according to bone mineral density.

4. Describe the pharmacologic effects of calcium and vitamin D on the skeleton, and recite the NIH Consensus Conference guidelines regarding optimal calcium intake.

5. Outline the guidelines from the American Association of Clinical Endocrinologists, and the National Osteoporosis Foundation on the diagnosis, prevention, and management of osteoporosis.

6. Describe the current controversies regarding hormone replacement therapy (HRT) with respect to treatment of osteoporosis.

7. Outline the role of bisphosphonates, calcitonin, selective estrogen receptor modulators (SERMs), and hormone replacement therapy (HRT) in the management of osteoporosis, and describe their clinical efficacy, mechanisms of action, precautions, administration guidelines, and adverse effects.

8. Describe the role of phytoestrogens and other investigational drug therapies, such as parathyroid hormone in the prevention and/or treatment of postmenopausal bone loss.

Privacy Policy / Disclaimer